In 2022, Walvax's Recombinant Bivalent Human Papillomavirus Vaccine (Types 16/18) (HPV-2) was launched. SARS-CoV-2 mRNA vaccine (AWcorna) was authorized under Indonesia EUA. 13-valent Pneumococcal Polysaccharide Conjugate Vaccine was Exported to Morocco and included in the National Immunization Program.
In 2020, at the COVID-19 outbreak, Walvax has led the efforts in developing 2 vaccinology for the SARS-CoV-2 virus, which are mRNA vaccinology and recombinant subunit vaccinology.
In 2019, Walvax identified 10-year development strategy which is to achieve internationalization, Industry 4.0 and import substitution. 13-valent Pneumococcal Polysaccharide Conjugate Vaccine was launched. Walvax received USD2.5 million from Bill & Melinda Gates Foundation to expedite the development of HPV9 vaccines.
In 2018, Group A and C Meningococcal Polysaccharide Vaccine was Exported to Egypt and included in the National Immunization Program.
In 2017, Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine were launched in China, and Group ACYW135 Meningococcal Polysaccharide Vaccine was exported to Indonesia.
In 2015, Walvax built partnership with Bill & Melinda Gates Foundation.
In 2012, Group A and C Meningococcal Polysaccharide Vaccine and Group ACYW135 Meningococcal Polysaccharide Vaccine were launched, and Haemophilus Influenzae Type b Conjugate Vaccine was officially exported to the Philippines.
In 2010, Walvax was listed on the Growth Enterprise Market (GEM) of Shenzhen Stock Exchange (SZSE). The stock name is abbreviated to “Walvax Biotechnology”, with the stock code of “300142”.
In 2009, Group A and Group C Meningococcal Conjugate Vaccine was launched.
In 2007, Walvax’s first independently developed and industrialized vaccine product, Haemophilus Influenzae Type b Conjugate Vaccine, was launched.
In 2004, Walvax commenced the construction of Yuxi Manufacturing Base.